The Endothelin System in Cardiopulmonary Diseases
Read Online
Share

The Endothelin System in Cardiopulmonary Diseases

  • 571 Want to read
  • ·
  • 74 Currently reading

Published by Reinhardt Druck Basel .
Written in English


Book details:

The Physical Object
FormatHardcover
Number of Pages263
ID Numbers
Open LibraryOL12861423M
ISBN 103724513364
ISBN 109783724513360

Download The Endothelin System in Cardiopulmonary Diseases

PDF EPUB FB2 MOBI RTF

Abstract There is considerable evidence that the potent vasoconstrictor endothelin‐1 (ET‐1) contributes to the pathogenesis of a variety of cardiovascular diseases. As such, pharmacological manipulation of the ET system might represent a promising therapeutic by:   Abnormalities of circulating endothelin-1 concentrations have also been observed in a number of conditions characterised by abnormal vasoconstriction such as hypertension, congestive heart failure (CHF), primary pulmonary hypertension (PPH), and hypoxaemic cor pulmonale, raising the possibility that endothelin-1 may play a pathogenic role in both cardiovascular and cardiopulmonary disease. As the physiological effects of endothelin-1 Cited by: Endogenous ET-1 may be involved in progression of various cardiovascular diseases. ET antagonists are currently used clinically in the treatment for patients with pulmonary hypertension, and are considered to have further target diseases as heart failure, cardiac hypertrophy and other cardiac diseases, renal diseases, systemic hypertension, and cerebral by: 6. Therefore, endothelin antagonists may play an important role in the treatment of cardiac, vascular and renal diseases associated with regional or systemic vasoconstriction and cell proliferation.

The role of the cardiac endothelin system in heart failure. Oliver Zolk and Michael Bo According to the Centre for Disease Prevention and Control of Latvia data, in latvians died. Gray GA, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther. ; 72 (2)– Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin Circulation. Oct 1; 94 (7)– Cellular and molecular biology of endothelin ET-1 was named after the cells that were first known to produce it: endothelial cells. It is now recognized that ET-1 is produced by a variety of other cells including vascular smooth muscle cells,7 leukocytes, cardiac myocytes,8,9 mesangial cells,10 neurons,11 mast cells,12 and macrophages ET-1 belongs to a family of closely related peptides. Endothelins are amino acid vasoconstricting peptides produced primarily in the endothelium having a key role in vascular homeostasis. Endothelins are implicated in vascular diseases of several organ systems, including the heart, lungs, kidneys, and brain. As of , endothelins remain under extensive basic and clinical research to define their roles in several organ systems.

Endothelin is a potent vasoconstrictor that when infused chronically leads to increases in blood pressure (Wilkins et al., ). Endothelin has been shown to be up-regulated during Ang II infusion (Alexander et al., ). Therefore, if aging is associated with activation of the RAS, then the increased synthesis of endothelin could play a role in the Ang II mediated increase in blood pressure with aging.   This first book on endothelins summarizes the early events which lead to the discovery of endothelin, the progress made in understanding the peptide's physiological role, and the current state-of-the-art in contemporary endothelin research. The book also discusses the potential significance of endothelins in health and disease, covers the.   Abnormal activation of the endothelin system can promote cardiovascular disease, pulmonary hypertension and kidney diseases. A great body of evidence shows that blocking of ET receptors is beneficial in improving the prognosis of idiopathic pulmonary hypertension, and therapeutic interventions in other cardiovascular - and renal diseases - are being addressed by . The discovery of endothelin‐1 (ET‐1) almost 20 years ago (Yanagisawa et al., ) was rapidly followed by the realization that its release, perhaps from a dysfunctional endothelium, could have a major role in the pathogenesis of a variety of cardiovascular diseases (reviewed by Haynes and Webb, and Rubanyi and Polokoff, ). This offered the tantalizing prospect that pharmacological manipulation .